New drugs for breast cancer
Laura Tookman1, Rebecca Roylance
1Centre for Molecular Oncology and Imaging, Barts and the London School of Medicine and Dentistry, John Vane Science Centre, Charterhouse Square, London, UK.
Abstract:
Recently there have been significant advances in rational drug design for the treatment of breast cancer, especially in the area of targeted drug therapy. These include drugs which target the HER2 receptor and angiogenesis and the novel class of drug the PARP inhibitors. Some of these agents, for example, trastuzumab used in the treatment of HER2 positive breast cancer are already established as the standard of care. However, the duration of adjuvant trastuzumab, whether to continue it beyond progression in metastatic disease and the mechanism for developing trastuzumab resistance, remain to be determined. There is also much still to be learnt regarding other targeted therapies; the efficacy of different agents, the optimal duration of use and combination of therapies. Many of these agents are already in clinical trials, the results of which are likely to change clinical practice.
Insights
Recent advances in breast cancer treatment include targeted therapies like HER2 inhibitors and PARP inhibitors. Further research is needed to optimize their use, duration, and overcome resistance for improved patient outcomes.
Area of Science:
- Oncology
- Pharmacology
- Genetics
Background:
- Significant progress in rational drug design for breast cancer treatment.
- Targeted therapies, including HER2 receptor and angiogenesis inhibitors, and PARP inhibitors, represent a major advancement.
- Trastuzumab is an established standard of care for HER2-positive breast cancer.
Purpose of the Study:
- To review recent advances in targeted drug therapy for breast cancer.
- To identify areas requiring further investigation, such as optimal duration of adjuvant trastuzumab and treatment beyond progression.
- To explore the mechanisms of trastuzumab resistance and the efficacy of other targeted agents.
Main Methods:
- Literature review of recent advancements in breast cancer targeted therapies.
- Analysis of current clinical trials and their potential impact on practice.
- Discussion of established and emerging targeted agents, including their mechanisms and clinical applications.
Main Results:
- Trastuzumab is a key treatment for HER2-positive breast cancer, but questions regarding its optimal use and resistance persist.
- Novel targeted therapies, such as PARP inhibitors, show promise but require further evaluation.
- Ongoing clinical trials are investigating efficacy, optimal duration, and combinations of targeted therapies.
Conclusions:
- Targeted drug therapy has significantly advanced breast cancer treatment.
- Further research is crucial to determine optimal treatment strategies, duration, and combinations for various targeted agents.
- Understanding and overcoming resistance mechanisms are essential for maximizing the benefit of targeted therapies in breast cancer.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:15Drugs that Stabilize Microtubules
02:18Cancer
02:56Treatment Resistent Cancers
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...